|
|
|
|
|
|
|
Acta Medica Medianae
Correspondence to:
Medicinski fakultet Bulevar dr Zorana Đinđića 81 18000 Niš, Srbija Tel.: 018/326384 E-mail:pedjamicro@bankerinter.net
Copyright 2007 by Faculty of Medicine, University of Nis |
TREATMENT OF CLOSTRIDIUM DIFFICILE- ASSOCIATED DISEASE
Predrag Stojanovic , Branislava Kocic, Gordana Randjelovic, Dobrila Stankovic-Djordjevic, Biljana Miljkovic-Selimovic, Snezana Antic-Mladenovic, Kristina Stojanovic and Tatjana Babic
Faculty of Medicine in Nis* Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacillus that is widely distributed in the environment, but is found as a part of a normal large bowel flora in approximately 3% of normal adults. C. difficile produces two protein exotoxins: toxin A and toxin B. Both toxins are responsible for causing the sings and symptoms of disease. C. difficile is now thought to be responsible for a spectrum of diseases, ranging from asymptomatic colonization to diarrhea of varying severity, life-threatening colitis, often as a consequence of long-term antibiotic exposure. This spectrum has become known as C. difficile-associated disease (CDAD). Treatment of Clostridium difficile-associated disease demand administration of effi-cient antibiotics (vancomycin, metronidazole), anion exchange resins and probiotics (Lactobacillus spp., Saccharomyces boulardii). Acta Medica Medianae 2007;46(2):31-36.
Key words: Clostridium difficile, CDAD, treatment |
